Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
October 29, 2024 6:45 AM EDTThird-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio Raises Full-Year 2024 Revenue Guidance(1) to a Range of $61.0 to $64.0 Billion and Raises Adjusted(2) Diluted EPS Guidance to a Range of $2.75 to $2.95 Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth Excluding Contributions from Paxlovid and Comirnaty(3), Revenues Grew 14% Operationally Third-Quarter 2024 Reported(4) Diluted EPS of $0.78 and Adjusted(2) Diluted EPS of $1.06 On Track to Deliver Net Cost Savings of At Least $5.5 Billion from Previously Announced Cost Reduction... More
